Sanofi buys Principia Biopharma for 3.11 billion euros

Merger between Sanofi and Principia Biopharma

Merger between Sanofi and Principia Biopharma.

The French pharmaceutical Sanofi has reached a “definitive agreement” to acquire the US laboratory Principia Biopharma for 3.68 billion dollars (3.11 billion euros) in cash, according to the companies, which expect to complete the transaction in the fourth quarter of 2020.

According to the conditions of the operation, which has the unanimous support of the boards of directors of both companies, Sanofi will pay $ 100 in cash for each Principia Biopharma share, which represents a premium of 10% over the closing price of the titles of the company last Friday.

Once the transaction is completed, a Sanofi subsidiary will merge with Principia and all the shares that have not joined the purchase will be converted into collection rights of the same price as the one paid during the offer, which will begin this month.

“This acquisition advances our R&D transformation to accelerate the development of medicines to treat significant patient needs,” said Paul Hudson, CEO of Sanofi.

“The combination with Sanofi will bring substantial resources to expand and accelerate the potential benefits of the therapies,” said Martin Babler, president and CEO of Principia Biopharma.

Breathonix develops non-invasive breath tests for disease detection

Breathonix develops non-invasive breath tests for disease detection. Singapore’s Breathonix has said a clinical trial of its COVID-19 breathalyzer test Read more

Moderna prepares for the "commercial launch" of its vaccine

Moderna prepares for the "commercial launch" of its vaccine. Modern biotechnology begins the procedures to request the authorization of its Read more

Grifols starts the trial to test its immunoglobulin in patients with Covid-19

Grifols starts the trial to test its immunoglobulin in patients with Covid-19. Grifols has announced the start of the clinical Read more

Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express

Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express. Preclinical biotech Foghorn Therapeutics Read more

CytoDyn rejected by the FDA

CytoDyn rejected by the FDA. The FDA rejected CytoDyn’s application for its lead program, an antibody to treat HIV in Read more

genetically modified mosquitoes for the field

Genetically modified mosquitoes for the field. A British biotech company has approval to release genetically modified mosquitoes into the Florida Read more

Moderna lab, the small biotechnology that can save the world from COVID-19

Moderna lab, the small biotechnology that can save the world from COVID-19. Moderna is using a new technology: instead of Read more

Moderna claims its COVID-19 vaccine produces a "robust" immune response

Moderna claims its COVID-19 vaccine produces a "robust" immune response. Scientists around the world will continue to search for a Read more

Leave a Reply